ALSO NOTED: Depomed surges on new data; FDA OKs Biomira study; and much more...

> Shares of Depomed surged on the news that a Phase II trial has produced data that demonstrates significantly reduced pain scores for patients taking one of two doses of its Gabapentin GR painkiller. Report

> Biomira and the FDA have agreed on a clinical trial design to test Stimuvax for advanced lung cancer. Report

> Genentech announced that an interim analysis shows that a randomized Phase III clinical study of Avastin in combination with interferon alfa-2a therapy in patients with first-line metastatic renal cell carcinoma met the primary analysis endpoint by significantly improving progression-free survival compared to interferon alfa-2a therapy alone. Report

> Alnylam Pharmaceuticals is selling 4.7 million common shares. Report

> Gloucester Pharmaceuticals has released interim data for romidepsin, its histone deacetylase inhibitor. Release

> Newly-launched London Genetics plans to facilitate partnerships between industry and academic centers of excellence in genetics and genomics-based research across London. Release

And Finally… Scientists have been making progress in developing new tests that can detect Alzheimer's at an early stage. Article